Founded in Sweden in 2012, IRRAS is a commercial medical device company, focused on designing, developing, and commercializing innovative solutions that transform fluid management after surgical procedures where drainage is required. Our initial clinical focus is on neurosurgical procedures, where excess cerebrospinal fluid (CSF) often needs to be drained and intracranial pressure (ICP) needs to be closely regulated.
IRRAS’ first commercial product, IRRAflow®, is a next generation intracranial fluid management system that consists of a patented dual lumen catheter, intelligent cassette, and control unit with proprietary software that work together to manage the drainage of excess fluid, intelligently manage the regulation of the patient’s ICP, and, on a regular basis, proactively flush the catheter to enable active fluid exchange.
These catheter blockages occur up to 40% of the time1 with legacy drainage systems and can result in inefficient drainage and excessively high infection rates2, and IRRAflow’s intelligent fluid exchange helps to address these shortcomings and provide a new standard of care for how Neuro ICU patients are managed.
Through continued technological advances, we remain focused on developing innovative features for IRRAflow as well as new products based on our core fluid exchange technologies. In the future, we envision new therapeutic applications for the IRRAflow platform, including targeted drug delivery and drainage in other clinical areas, such as abdominal surgery.
IRRAS is traded on the NASDAQ Stockholm Main Market exchange in Stockholm under the symbol IRRAS and is headquartered in Stockholm, Sweden, with offices in Munich, Germany, and San Diego, California.
Develop multiple groundbreaking applications for IRRAflow technology.
Launch of IRRAflow in some key markets after registration approval has been obtained.
Develop IRRAflow for treatment in other parts of the body.
US FDA 510(k) clearance received for IRRAflow.
Receipt of ISO 13485:2016 Certification.
Launch in the US and other key markets. Launch of new catheter to IRRAflow.
IRRAS completes IPO and is currently listed on NASDAQ Stockholm.
Began to establish IRRAS and IRRAflow as an innovative solution for managing intracranial bleeding.
Mezzanine financing round is completed.
IRRAS operations were established in California.
ISO Certification first received in EU.
The company expands its intellectual property portfolio with the acquisition of its first patent family.
Work on developing and commercializing IRRAflow begins.
IRRAS AB is founded as a joint venture between Serendipity Innovations AB, Vandel Group and Jaymore Enterprises Limited.
Patent belonging to the first patent family granted by the European Patent Office (EPO).
1. Fargen KM, Hoh BL, Neal D, O’Connor T, Rivera-Zengotita M, Murad GJ. The burden and risk factors of ventriculostomy occlusion in a high-volume cerebrovascular practice: results of an ongoing prospective database. Journal of Neurosurgery. 2015:1-8.
2. Citerio G, Signorini L, Bronco A, Vargiolu A, Rota M, Latronico N. External Ventricular and Lumbar Drain Device Infections in ICU Patients: A Prospective Multicenter Italian Study. Crit Care Med. 2015 Aug;43(8):1630-7.